Enhanced cutaneous vascular response in AD subjects under donepezil therapy

Neurobiology of Aging

Volumn 25, Issue 4, 2004, Pages 475-481

  Maltz, Jonathan S ^a   Eberling, Jamie L ^a,b   Jagust, William J ^b   Budinger, Thomas F ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Cutaneous perfusion; Donepezil; Iontophoresis; Laser Doppler imaging

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; METHACHOLINE CHLORIDE; NITROPRUSSIDE SODIUM;

ALZHEIMER DISEASE; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; FOREARM; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; PRIORITY JOURNAL; SKIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; DRUG SYNERGISM; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; SKIN; VASODILATION; VASODILATOR AGENTS;

EID: 1542298228     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00124-6     Document Type: Article

References (29)

1. Algotsson A., Nordberg A., Almkvist O., Winblad B. Skin vessel reactivity is impaired in Alzheimer's disease. Neurobiol. Aging. 16(4):1995;577-582.
2. Algotsson A. Serum lipids and lipoproteins are correlated to skin vessel reactivity in healthy women. J. Intern. Med. 239(2):1996;147-152.
3. Algotsson A., Nordberg A., Winblad B. Apolipoprotein E ε4 allele has an impact on vascular reactivity in Alzheimer's disease. Arch. Gerontol. Geriatr. 31(3):2000;221-231.
4. Algotsson A. Skin vessel reactivity tests in healthy middle-aged subjects: the influence of depolarizing current and serum lipids. Arch. Gerontol. Geriatr. 34:2002;135-144.
5. Aronson M.K., Ooi W.L., Morgenstern H., Hafner A., Masur D., Crystal H. et al. Women, myocardial infarction and dementia in the very old. Neurology. 40(7):1990;1102-1106.
6. Bisoendial R.J., Hovingh G.K., De Groot E., Kastelein J.J., Lansberg P.J., Stroes E.S. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr. Opin. Lipidol. 13(6):2002;595-603.
7. Breteler M.M.B. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N.Y. Acad. Sci. 903:2000;457-465.
8. Davidsson P., Blennow K., Andreasen N., Eriksson B., Minthon L., Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci. Lett. 300(3):2001;157-160.
9. de la Torre J.C. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann. N.Y. Acad. Sci. 924:2000;136-152.
10. de Man F.H., Weverling-Rijnsburger A.W., van der Laarse A., Smelt A.H., Jukema J.W., Blauw G.J. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. Arterioscler. Thromb. Vasc. Biol. 20(3):2000;744-750.
11. Etsuda H., Takase B., Uehata A., Kusano H., Hamabe A., Kuhara R.et al. Morning attenuation of endothelium-dependent, flow-mediated dilation in healthy young men: possible connection to morning peak of cardiac events? Clin. Cardiol. 22(6):1999;417-421.
12. Hachinski V., Munoz D.G. Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomenon? Ann. N.Y. Acad. Sci. 826:1997;1-6.
13. Hachinski V., Munoz D. Vascular factors in cognitive impairment - where are we now? Ann. N.Y. Acad. Sci. 903:2000;1-5.
14. Hofman A., Ott A., Breteler M.M., van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349(9046):1997;151-154.
15. Hornqvist R., Henriksson R., Back O., Bucht G., Winblad B. Iontophoretic study of adrenergic and cholinergic skin vessel reactivity in normal ageing and Alzheimer's disease. Gerontology. 33(6):1987;374-379.
16. Imbimbo B.P. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 15(5):2001;375-390.
17. Joseph L.J., Ryan A.S., Sorkin J., Mangano C., Brendle D.C., Corretti M.C.et al. Body fat distribution and flow-mediated endothelium-dependent vasodilation in older men. Int. J. Obes. Relat. Metab. Disord. 26(5):2002;663-669.
18. Kalman J., Szakacs R., Torok T., Rozsa Z., Barzo P., Rudas L.et al. Decreased cutaneous vasodilatation to isometric handgrip exercise in Alzheimer's disease. Int. J. Geriatr. Psychiatry. 17(4):2002;371-374.
19. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 58(11):2003;719-731.
20. Lindman HR. Analysis of variance in experimental design. New York: Springer-Verlag; 1991.
21. Martin C.M., Beltran-Del-Rio A., Albrecht A., Lorenz R.R., Joyner M.J. Local cholinergic mechanisms mediate nitric oxide-dependent flow-induced vasorelaxation in vitro. Am. J. Physiol. 270(2 Pt 2):1996;H442-H446.
22. Morris M.C., Scherr P.A., Hebert L.E., Bennett D.A., Wilson R.S., Glynn R.J.et al. The cross-sectional association between blood pressure and Alzheimer's disease in a biracial community population of older persons. J. Gerontol. A Biol. Sci. Med. Sci. 55(3):2000;M130-M136.
23. Nakano S., Asada T., Matsuda H., Uno M., Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J. Nucl. Med. 42(10):2001;1441-1445.
24. Omori H., Nagashima H., Tsurumi Y., Takagi A., Ishizuka N., Hagiwara N. et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br. J. Clin. Pharmacol. 54(4):2002;395-399.
25. Peruzzi P., Von Euw D., Lacombe P. Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels. Ann. N.Y. Acad. Sci. 903:2000;394-406.
26. Price J.M., Chi X., Hellermann G., Sutton E.T. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol. Res. 23(5):2001;506-512.
27. Schroeder S., Enderle M.D., Baumbach A., Ossen R., Herdeg C., Kuettner A.et al. Influence of vessel size age and body mass index on the flow-mediated dilatation (FMD%) of the brachial artery. Int. J. Cardiol. 76(2/3):2000;219-225.
28. Sramek J.J., Cutler N.R. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer Dis. Assoc. Disord. 14(4):2000;216-227.
29. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38(24):1995;4821-4829.